This Market Spotlight report covers the Opioid-Induced Constipation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 28 February 2022
Number of pages:23
This Market Spotlight report covers the Opioid-Induced Constipation (OIC) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and epidemiology data, as well as presenting drug-specific revenue forecasts.
The approved drugs in the opioid-induced constipation (OIC) space predominantly target opioid receptors, with the exception of Amitiza, a type-2 chloride channel activator. All of the marketed drugs are administered via the oral route, with one product also being available in a subcutaneous formulation.
There are currently no pipeline candidates in development for OIC. The overall likelihood of approval of a Phase I gastroenterology (non inflammatory bowel disease)-other asset is 14%, and the average probability a drug advances from Phase III is 59%. Drugs, on average, take 10.3 years from Phase I to approval, compared to 10.1 years in the overall gastroenterology (non inflammatory bowel disease) space.
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for OIC have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
Clinical trial activity in the OIC space is dominated by completed trials. Progenics Pharmaceuticals has the highest number of completed clinical trials for OIC, with 13 trials.
Progenics Pharmaceuticals leads the industry sponsors with the highest overall number of clinical trials for OIC, followed by Pfizer
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 Management of OIC with laxatives
8 Management of OIC with opioid antagonists
9 Management of OIC with Amitiza, a secretagogue chloride channel activator
15 LICENSING AND ASSET ACQUISITION DEALS
15 MSN Deals Out Of Movantik But Two ANDA Filers Remain
16 REVENUE OPPORTUNITY
18 CLINICAL TRIAL LANDSCAPE
19 Sponsors by status
19 Sponsors by phase
LIST OF FIGURES
14 Figure 1: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
18 Figure 2: Clinical trials in OIC
18 Figure 3: Top 10 drugs for clinical trials in OIC
19 Figure 4: Top 10 companies for clinical trials in OIC
19 Figure 5: OIC trials sponsors by status
20 Figure 6: OIC trials sponsors, by phase
LIST OF TABLES
12 Table 1: Marketed drugs for OIC
16 Table 2: Historical global sales, by drug ($m), 2016–20
17 Table 3: Forecasted global sales, by drug ($m), 2022–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726